BriaCell Therapeutics Corp. (BCTX)
3.575
0.00 (0.00%)
USD |
NASDAQ |
Sep 08, 16:00
3.54
-0.04
(-0.98%)
After-Hours: 20:00
BriaCell Therapeutics Max Drawdown (5Y) : 99.85% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 99.85% |
| July 31, 2026 | 99.85% |
| June 30, 2026 | 99.85% |
| May 31, 2026 | 99.83% |
| April 30, 2026 | 99.79% |
| March 31, 2026 | 99.79% |
| February 28, 2026 | 99.79% |
| January 31, 2026 | 99.76% |
| December 31, 2025 | 99.65% |
| November 30, 2025 | 99.65% |
| October 31, 2025 | 99.65% |
| September 30, 2025 | 99.65% |
| August 31, 2025 | 99.65% |
| July 31, 2025 | 99.58% |
| June 30, 2025 | 98.75% |
| May 31, 2025 | 98.75% |
| April 30, 2025 | 98.75% |
| March 31, 2025 | 98.75% |
| February 28, 2025 | 98.75% |
| January 31, 2025 | 98.32% |
| December 31, 2024 | 97.64% |
| November 30, 2024 | 97.64% |
| October 31, 2024 | 97.64% |
| September 30, 2024 | 97.64% |
| August 31, 2024 | 97.23% |
| Date | Value |
|---|---|
| July 31, 2024 | 96.54% |
| June 30, 2024 | 95.17% |
| May 31, 2024 | 93.13% |
| April 30, 2024 | 91.03% |
| March 31, 2024 | 91.03% |
| February 29, 2024 | 91.03% |
| January 31, 2024 | 91.03% |
| December 31, 2023 | 91.03% |
| November 30, 2023 | 91.03% |
| October 31, 2023 | 91.03% |
| September 30, 2023 | 91.03% |
| August 31, 2023 | 91.03% |
| July 31, 2023 | 91.03% |
| June 30, 2023 | 91.03% |
| May 31, 2023 | 91.03% |
| April 30, 2023 | 91.03% |
| March 31, 2023 | 91.03% |
| February 28, 2023 | 91.03% |
| January 31, 2023 | 91.03% |
| December 31, 2022 | 91.03% |
| November 30, 2022 | 91.03% |
| October 31, 2022 | 91.03% |
| September 30, 2022 | 91.03% |
| August 31, 2022 | 91.03% |
| July 31, 2022 | 91.03% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Edesa Biotech, Inc. | 99.04% |
| ProMIS Neurosciences, Inc. | 97.95% |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -81.34 |
| Beta (5Y) | 1.096 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 87.72% |
| Historical Sharpe Ratio (5Y) | -0.814 |
| Historical Sortino (5Y) | -1.277 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 42.00% |